A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

102

Participants

Timeline

Start Date

November 10, 2025

Primary Completion Date

July 14, 2032

Study Completion Date

July 14, 2032

Conditions

Advanced Solid TumorMetastatic Solid Tumor

Interventions

BIOLOGICAL

IPN01203

Study intervention will be provided in a vial.